Efficacy of Lactobacillus GG in prevention of nosocomial diarrhea in infants

Szajewska, Hania; Kotowska, Maria; Mrukowicz, Jacek; Arma′nska, Malgorzata; Mikolajczyk, W

doi:10.1067/mpd.2001.111321

Cited by 355 publications

(229 citation statements)

References 35 publications

Supporting

Mentioning

214

Contrasting

Unclassified

Order By: Relevance

“…Some placebocontrolled studies also suggest that probiotics are of benefit in the treatment of antibiotics-associated diarrhoea and in the prevention of nosocomial diarrhoea in infants (Szajewska et al, 2001;Cremonini et al, 2002). The putative mechanisms of L. rhamnosus GG action may include stimulation of the cell proliferation rate of bowel epithelial cells, enhanced secretion of protective mucins leading to reduced adherence of enteropathogenic bacteria to the bowel wall, inhibition of bacterial translocation into the tissues, and stimulation of local and systemic immune response to pathogens (Mattar et al, 2001;Banasaz et al, 2002;Khaled et al, 2003;Mack et al, 2003;Vaarala, 2003).…”

mentioning

confidence: 99%

Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study

et al. 2007

View full text Add to dashboard Cite

5-Fluorouracil (5-FU)-based chemotherapy is frequently associated with diarrhoea. We compared two 5-FU-based regimens and the effect of Lactobacillus and fibre supplementation on treatment tolerability. Patients diagnosed with colorectal cancer (n ¼ 150) were randomly allocated to receive monthly 5-FU and leucovorin bolus injections (the Mayo regimen) or a bimonthly 5-FU bolus plus continuous infusion (the simplified de Gramont regimen) for 24 weeks as postoperative adjuvant therapy. On the basis of random allocation, the study participants did or did not receive Lactobacillus rhamnosus GG supplementation (1 -2 Â 10 10 per day) and fibre (11 g guar gum per day) during chemotherapy. Patients who received Lactobacillus had less grade 3 or 4 diarrhoea (22 vs 37%, P ¼ 0.027), reported less abdominal discomfort, needed less hospital care and had fewer chemotherapy dose reductions due to bowel toxicity. No Lactobacillus-related toxicity was detected. Guar gum supplementation had no influence on chemotherapy tolerability. The simplified de Gramont regimen was associated with fewer grade 3 or 4 adverse effects than the Mayo regimen (45 vs 89%), and with less diarrhoea. We conclude that Lactobacillus GG supplementation is well tolerated and may reduce the frequency of severe diarrhoea and abdominal discomfort related to 5-FU-based chemotherapy.

show abstract

mentioning

confidence: 99%

Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study

et al. 2007

View full text Add to dashboard Cite

show abstract

“…In general, probiotics should be administered for at least 5 days and, in any case, for the duration of hospitalization, in one or two daily doses. The effect is most evident in cases of early treatment of rotavirus infection with oral rehydration therapy associated with Lactobacillus GG [54][55][56][57]. This probiotic is able to decrease the excretion of rotavirus in the stool [58], helping to reduce the spread of the virus, in turn improving the effectiveness of preventive strategies both in communities and during hospitalization.…”

Section: Infectious Gastroenteritismentioning

confidence: 99%

“…Yet, definitive conclusions cannot be drawn based on the available results [59][60][61]. The effectiveness of treatment with probiotics is demonstrated in mild-to moderateseverity rotavirus gastroenteritis, while the results obtained in the treatment of rotavirus negative forms and, especially, in bacterial infections are inconclusive [54,61]. It has been hypothesized that the ineffectiveness of LGG in bacterial diarrhea is due to the ability of bacteria to produce mucinases that neutralize the effects of probiotics [62].…”

Section: Infectious Gastroenteritismentioning

confidence: 99%

Probiotics and health: An evidence-based review

Aureli

Capurso

Castellazzi

et al. 2011

Pharmacological Research

232

131

View full text Add to dashboard Cite

a b s t r a c tThe intestinal microbiota is an ecosystem formed by a variety of ecological niches, made of several bacterial species and a very large amount of strains. The microbiota is in close contact with the intestinal mucosa or epithelial interface which is, after the respiratory area, the largest surface of the body, occupying approximately 250-400 m 2 . The physiological activities of the microbiota are manifold and are just being unraveled. Based on the observations of the multiple roles played by the microbiota in health and disease, the notion of modifying it with appropriate formulations, i.e. probiotics, is being tested in several settings.This review summarizes the current knowledge on probiotics and discusses both limitations and acquired evidence to support their use in preventive and therapeutic medicine.

show abstract

“…These interactions result in an increase in the number of IgAproducing cells accompanied by the production of secretory IgM and IgA that are particularly important to the immunity of the mucosa, contributing to the barrier against pathogenic micro-organisms ( Szajewska et al, 2001).…”

Section: Introductionmentioning

confidence: 99%